Results 191 to 200 of about 146,874 (392)

Prescription for the People: An Activist\u27s Guide to Making Medicine Affordable for All [PDF]

, 2017
[Excerpt] Because every cure starts with an accurate diagnosis, in this book I explain how and why the current medicines system is dysfunctional and corrupt.
Quigley, Fran
core   +1 more source

Pathway‐level mutational signatures predict breast cancer outcomes and reveal therapeutic targets

British Journal of Pharmacology, EarlyView.
Abstract Background and Purpose In order to significantly improve the therapeutic treatment of breast cancer, the exploration of underlying genetic and molecular differences is absolutely necessary. Here, our goal was to integrate mutational status of entire pathways to reveal molecular pathway interactions determining survival. Experimental Approach A
Máté Posta, Balázs Győrffy
wiley   +1 more source

Trastuzumab combined with chemotherapy for the treatment of HER2-positive metastatic breast cancer: Pivotal trial data

, 2001
W. Eiermann
openalex   +1 more source

The HER-2-Targeting Antibodies Trastuzumab and Pertuzumab Synergistically Inhibit the Survival of Breast Cancer Cells [PDF]

, 2004
Rita Nahta, Mien‐Chie Hung, Francisco J. Esteva   +2 more
openalex   +1 more source

Trastuzumab emtansine for HER2-positive advanced breast cancer.

New England Journal of Medicine, 2012
S. Verma, D. Miles, L. Gianni, I. Krop, M. Welslau, J. Baselga, M. Pegram, D. Oh, V. Diéras, E. Guardino, L. Fang, Michael W. Lu, S. Olsen, K. Blackwell   +13 more
semanticscholar   +1 more source

Efficacy and Safety of T‐DXd in HER2+ and Low/Zero Metastatic BCBM: A Retrospective Multicenter Real‐World Study

Cancer Science, EarlyView.
This real‐world study provides critical evidence supporting the efficacy and safety of T‐DXd in HER2‐positive and HER2‐low breast cancer brain metastases (BCBM), including patients with active/symptomatic disease, leptomeningeal involvement, and poor performance status, thereby addressing unmet needs in clinical practice.
Qingru Zhou, Yuanyuan Li, Ni He, Guorong Zou, Mengqian Ni, Lulu Zhang, Shu Dun, Zhanhong Chen, Kejun Liu, Yabing Cao, Jiajia Huang, Fei Xu, Zhongyu Yuan, Shusen Wang, Yanxia Shi, Yonggao Mou, Anli Yang, Lixia Li, Xin An   +18 more
wiley   +1 more source

Future directions in the adjuvant treatment of breast cancer: The role of trastuzumab

, 2001
Ian Smith
openalex   +1 more source

Monitoring of Serum Her-2/ neu Predicts Response and Progression-Free Survival to Trastuzumab-Based Treatment in Patients with Metastatic Breast Cancer [PDF]

, 2004
Wolfgang J. Köstler, Barbara Schwab, Christian F. Singer, Rainer Neumann, Ernst Rücklinger, Thomas Brodowicz, Sandra Tomek, Monika Niedermayr, Michael Hejna, Günther Steger, Michael Krainer, Christoph Wiltschke, Christoph Zielinski   +12 more
openalex   +1 more source

Trastuzumab

Swiss Medical Forum ‒ Schweizerisches Medizin-Forum, 2007
CK Baumann, M CastiglioneGertsch
openaire   +1 more source

Emergence of PALB2 Reversion Mutations as a Mechanism of Resistance to Niraparib in Breast Cancer: A Case Report

Cancer Science, EarlyView.
This case study describes the clinical course of a 39‐year‐old woman with metastatic breast cancer harboring a germline PALB2 mutation who was treated with a PARP inhibitor. Figure shows the PALB2 reverse mutation detected by liquid biopsy genomic profiling. The top panel shows a schematic diagram of the wild‐type PALB2 sequence. The second panel shows
Maako Kawamura, Hiroshi Tada, Hidekazu Shirota, Miki Dobashi, Noriko Takenaga, Hiroyuki Yasojima, Narumi Harada‐shoji, Keigo Komine, Kenichi Nakamura, Minoru Miyashita, Hisato Kawakami   +10 more
wiley   +1 more source